Skip to main content
. 2022 Dec 6;39(2):41–47. doi: 10.1007/s40267-022-00971-1

Fig. 1.

Fig. 1

BPA workflow for prescription of nirmatrelvir plus ritonavir to treat COVID-19, as suggested by Millstein et al. [31]. BPA best practice advisory, COVID-19 coronavirus disease 2019, DDI drug–drug interaction, eGFR estimated glomerular filtration rate